QbD-guided development and optimization of a rapid-disintegrating sublingual film of olanzapine.

AIM: Olanzapine is an atypical antipsychotic used to treat chronic schizophrenia and bipolar I disorder, including mixed/manic episodes. It is a BCS class II medication, and thus there is a potential for sublingual administration allowing rapid absorption. This may potentially result in a faster onset of action compared to oral tablets. The aim of this work was to formulate a fast-dissolving sublingual film of olanzapine with rapid disintegration. MATERIALS AND METHODS: drug release of films. RESULTS: dissolution studies estimated the release to be 94.79% in 10 min. CONCLUSION: assessment of the film are warranted to prove enhanced permeation indicating quicker absorption sublingually, leading to an increase in bioavailability.